Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. (Q53859210)

21 May 2018

title

Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. (English)

1 reference

21 May 2018

1 reference

Athanasios Dimopoulos

11

1 reference

21 May 2018

George Fountzilas

2

George Fountzilas

1 reference

21 May 2018

Dimitrios Pectasides

1

Dimitrios Pectasides

1 reference

21 May 2018

Dimosthenis Skarlos

8

Dimosthenis Skarlos

1 reference

21 May 2018

Theofanis Economopoulos

10

Theofanis Economopoulos

1 reference

21 May 2018

Gerasimos Aravantinos

3

Gerasimos Aravantinos

1 reference

21 May 2018

Evangelos Briasoulis

9

Evangelos Briasoulis

1 reference

21 May 2018

Eleni Efstathiou

5

Eleni Efstathiou

1 reference

21 May 2018

Dimitrios Farmakis

7

Dimitrios Farmakis

1 reference

21 May 2018

author name string

Haralampos P Kalofonos

4

1 reference

21 May 2018

Emmanouel Salamalekis

6

1 reference

21 May 2018

language of work or name

English

0 references

publication date

1 May 2005

1 reference

21 May 2018

published in

Gynecologic Oncology

1 reference

21 May 2018

volume

97

1 reference

21 May 2018

issue

2

1 reference

21 May 2018

page(s)

436-441

1 reference

21 May 2018

cites work

Cancer statistics, 2001

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Survival among U.S. women with invasive epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Nonparametric Estimation from Incomplete Observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Mucinous carcinoma of the ovary. Clinicopathologic analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Noninvasive, microinvasive, and invasive mucinous carcinomas of the ovary: a clinicopathologic analysis of 40 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2004.12.056

10.1016/J.YGYNO.2004.12.056

7 January 2021

Identifiers

DOI

1 reference

21 May 2018

1 reference

21 May 2018